Anti-CD19 Recombinant Immunotoxin DT-AntiCD19 (DT390-FMC63(scFv)) (CAT#: BioBet-IT009Z) Datasheet

CD19

CD19 Molecule

CD19 (CD19 Molecule) is a Protein Coding gene.Diseases associated with CD19 include Immunodeficiency, Common Variable, 3 and Common Variable Immunodeficiency. Among its related pathways are RET signaling and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. Gene Ontology (GO) annotations related to this gene include signal transducer activity, downstream of receptor.

CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; B-Lymphocyte Antigen CD19; CVID3; B4;

Entrez Gene: 930

UniProtKB: P15391

FMC63

Protein Based Therapies
Monoclonal antibody (mAb)

scFv

Mouse

Human

Based on comparative studies, antigen recognition and positive reaction with CD19 transfected cell lines, the specificity of this antibody is the same as that of CD19 monoclonal antibody (Zola et al., 1988, 1989). It can detect 96 kD single chain glycoproteins on the surface of human B lineage cells (including pre-B cells). B cells can be detected in peripheral blood and tissues. The antibody can react with most B-cell malignancies, including chronic lymphocytic leukemia and most lymphomas, but does not include multiple myeloma.

Cellular reactivity:
Normal: Stain all B lymphocytes in peripheral blood and spleen. It is negative for granulocytes, monocytes, platelets, red blood cells and T lymphocytes.

clinical:
B-cell chronic lymphocytic leukemia (B-CLL) +
Lymphocytic leukemia (PLL) +
Hairy cell leukemia (HCL) +
Common acute lymphocytic leukemia (CALL) +
Acute lymphocytic leukemia before B (before B-ALL) +
NULL Acute Lymphocytic Leukemia (NULL-ALL) +
Common T-lymphocytic leukemia (T-CLL)-

Refractory B-cell malignancies; B-cell Leukemia/Lymphoma

DT390

Corynebacterium

Diphtheria toxin

35.64kD

Diphtheria toxin (DT) is one of the most extensively studied bacterial toxins with intracellular action. The first 390 amino acid residues of DT (DT390) contain the catalytic domain or A chain of DT that inhibits protein synthesis by ADP ribosylation of elongation factor 2 (EF-2) and the translocation domain that translocates the catalytic domain to the cytosol by interaction with cytosolic Hsp90 and thioredoxin reductase.

The antibody portion mediated selective binding to target cells, while the toxin portion mediated translocation into the cytosol and subsequent cell killing.

Refractory B-cell malignancies; B-cell Leukemia/Lymphoma